- 米国企業
- UroGen Pharma Ltd.
UroGen Pharma Ltd.URGN
時価総額
$4.1億
PER
| 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | |
| Revenue | 8 | 1 | 0 | 12 | 48 | 64 |
| Cost of revenue | 1 | 2 | - | 1 | 5 | 8 |
| Gross profit | 8 | -1 | 0 | 11 | 43 | 57 |
| Research and development expenses | - | - | 49 | 47 | 48 | 53 |
| Selling, general and administrative expenses | - | - | - | 90 | 88 | 83 |
| Operating loss | -20 | -77 | -109 | -127 | -92 | -79 |
| Financing on prepaid forward obligation | - | - | - | - | 17 | 22 |
| Interest expense on long-term debt | - | - | - | - | - | 8 |
| Interest and other income, net | - | - | - | - | - | 1 |
| Loss before income taxes | -20 | -76 | -105 | -125 | -109 | -108 |
| Income tax expense | 0 | 0 | - | 3 | 1 | 2 |
| Net Loss | -20 | -76 | -105 | -128 | -111 | -110 |
| Net loss | -20 | -76 | -105 | -128 | -111 | -110 |
| Unrealized (loss) on investments | - | - | 0 | -0 | -0 | -0 |
| Comprehensive Loss | - | - | -105 | -128 | -111 | -110 |
| Net loss per ordinary share - basic and diluted (in dollars per share) | - | - | - | - | - | -4.81 |